6.
Mata M, Gerken C, Nguyen P, Krenciute G, Spencer D, Gottschalk S
. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov. 2017; 7(11):1306-1319.
PMC: 5780189.
DOI: 10.1158/2159-8290.CD-17-0263.
View
7.
Zah E, Lin M, Silva-Benedict A, Jensen M, Chen Y
. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. 2016; 4(6):498-508.
PMC: 4933590.
DOI: 10.1158/2326-6066.CIR-15-0231.
View
8.
Nouri Y, Weinkove R, Perret R
. T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. J Immunother Cancer. 2021; 9(11).
PMC: 8606765.
DOI: 10.1136/jitc-2021-003065.
View
9.
Keam S
. Afamitresgene Autoleucel: First Approval. Mol Diagn Ther. 2024; 28(6):861-866.
DOI: 10.1007/s40291-024-00749-3.
View
10.
Wang X, Jasinski D, Medina J, Spencer D, Foster A, Bayle J
. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020; 4(9):1950-1964.
PMC: 7218419.
DOI: 10.1182/bloodadvances.2020001510.
View
11.
Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G
. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025; 16(1):262.
PMC: 11695690.
DOI: 10.1038/s41467-024-55751-4.
View
12.
Yang D, Sun B, Dai H, Li W, Shi L, Zhang P
. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019; 7(1):171.
PMC: 6617951.
DOI: 10.1186/s40425-019-0642-9.
View
13.
Xu N, Palmer D, Robeson A, Shou P, Bommiasamy H, Laurie S
. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2020; 218(2).
PMC: 7780733.
DOI: 10.1084/jem.20200844.
View
14.
Obajdin J, Larcombe-Young D, Glover M, Kausar F, Hull C, Flaherty K
. Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Rep Med. 2024; 5(11):101827.
PMC: 11604534.
DOI: 10.1016/j.xcrm.2024.101827.
View
15.
Zhang E, Ma Z, Li Q, Yan H, Liu J, Wu W
. TLR2 Stimulation Increases Cellular Metabolism in CD8 T Cells and Thereby Enhances CD8 T Cell Activation, Function, and Antiviral Activity. J Immunol. 2019; 203(11):2872-2886.
DOI: 10.4049/jimmunol.1900065.
View
16.
Sterner R, Sterner R
. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69.
PMC: 8024391.
DOI: 10.1038/s41408-021-00459-7.
View
17.
Nimma S, Gu W, Maruta N, Li Y, Pan M, Saikot F
. Structural Evolution of TIR-Domain Signalosomes. Front Immunol. 2021; 12:784484.
PMC: 8635717.
DOI: 10.3389/fimmu.2021.784484.
View
18.
Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S
. MyD88/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight. 2020; 5(21).
PMC: 7710311.
DOI: 10.1172/jci.insight.136093.
View
19.
Majzner R, Mackall C
. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018; 8(10):1219-1226.
DOI: 10.1158/2159-8290.CD-18-0442.
View
20.
Thudium Mueller K, Waldron E, Grupp S, Levine J, Laetsch T, Pulsipher M
. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2018; 24(24):6175-6184.
PMC: 7433345.
DOI: 10.1158/1078-0432.CCR-18-0758.
View